MYT-109

N/A

Report date: 2024/11/13 15:02:33
NME

Base Information

Drug NameMYT-109
Drug Alias NameMYT-109
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear factor erythroid 2-related factor 2 stimulantsNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor erythroid 2-related factor 2Nuclear factor NF-kappa-B complex
Therapy Area/IndicationsOptic Atrophy, Hereditary, LeberFriedreich AtaxiaLeigh Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMyto Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMyto Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsOptic Atrophy, Hereditary, LeberFriedreich AtaxiaLeigh Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A